業績

Nomoto H.

Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes World J Diabetes

IF：4.560

令和4年度 北海道大学大学院医学研究院 優秀論文賞 阿部　靖矢先生

令和4年度 北海道大学大学院医学研究院 優秀論文賞 狩野　皓平先生

Takako Araki, Hiraku Kameda, Masaaki Yamamoto, Toru Tateno, Yasumasa Iwasaki, Run Yu, Constance Chik, Hiba Hashmi, Angela Radulescu, Lynn A Burmeister, Hidenori Fukuoka The impact of multi-cultural interfacility video case conference – A novel education model after the COVID pandemic – Journal of the Endocrine Society, in press.

IF：なし

Takahashi Y, Nomoto H*, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H*.

Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1

study)

Diabetes Obes Metab, in press

IF = 6.408

Miyoshi H, Matsuhisa M, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y.

Use of iGlarLixi for the management of type 2 diabetes in Japanese clinical practice: prior treatment subgroup analysis of the SPARTA Japan study.

Diabetes Ther. 2023 in press

IF = 3.605

Karino K, Kono M, Kanda M, Atsumi T.

Reply.

Arthritis Rheumatol. in press.

IF=15.483

Kato M, Ninagawa K, Atsumi T.

Comment on: Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study: Reply.

Rheumatology (Oxford). in press

IF=7.046

Aso K, Fujieda Y, Atsumi T.

Homonymous hemianopsia and headache with mass-like lesion Annals of the Rheumatic Diseases.

IF 19.103

Scherlinger M, Pan W, Hisada R, Boulougoura A, Yoshida N, Vukelic M, Umeda M, Krishfield S, Tsokos MG, Tsokos GC.

Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity.

Sci Adv. 2022;8(48):eadc9657.

IF = 14.980